Incretin modulators - Carmot Therapeutics
Latest Information Update: 01 Feb 2024
At a glance
- Originator Carmot Therapeutics
- Class Hepatoprotectants; Peptides
- Mechanism of Action Incretin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Lipodystrophy
Most Recent Events
- 29 Jan 2024 Carmot Therapeutics has been acquired by Roche
- 10 Feb 2021 Incretin modulators - Carmot Therapeutics is available for licensing as of 10 Feb 2021. https://carmot-therapeutics.us/partnerships/
- 10 Feb 2021 Early research in Lipodystrophy in USA (unspecified route) prior to February 2021 (Carmot Therapeutics pipeline, February 2021)